Popular diabetes medication also used for weight loss may pose a risk to vision
- 03/09/2026
- By Пентаграм
- 6
- News, Ophthalmology, Useful
The diabetes medication semaglutide (known in Bulgaria as Ozempic®) has made headlines around the world after receiving FDA (US Food and Drug Administration) approval for blood sugar control and obesity treatment.
Semaglutide can significantly help patients control their blood sugar, benefiting both their overall health and their eye health. Alongside the good news, however, studies have emerged showing that, in addition to benefiting vision, the medication may cause changes such as blurred vision, worsening diabetic retinopathy, and other eye health complications. So, do the benefits outweigh the risks? For a comment on the subject, we turned to one of the leading ophthalmologists at Pentagram Eye Hospital, Dr. Risto Trajkovski.
Ozempic® (semaglutide) was originally approved to treat type 2 diabetes, but because it suppresses appetite, it has become popular for weight loss outside its approved uses. According to clinical studies, GLP-1 significantly lowers blood sugar and helps people lose weight. Approximately 15 million people in the United States currently take GLP-1 medications. Off-label use is becoming increasingly common, which raises concerns about potential health risks and significant side effects.
Semaglutide and NAION (non-arteritic anterior ischemic optic neuropathy)
According to a study, 6,7% of overweight people and 8,9% of those with diabetes who took semaglutide had NAION.
NAION is a complex condition that usually affects people over 50. It is particularly common among people with health problems such as diabetes, high blood pressure, or obstructive sleep apnea. It involves sudden damage to the optic nerve due to interrupted or reduced blood flow to its front portion (the optic disc). The condition is often called an “eye stroke”.
The main symptoms include: sudden vision loss that occurs rapidly, usually in the morning upon waking. Vision loss is usually painless (unlike inflammatory neuritis) and is associated with visual field defects (most often affecting the lower or upper half of the visual field, and fog, a shadow, or a “curtain” may appear in front of the eye).
A retrospective cohort study involving 16,827 patients with neuro-ophthalmic conditions found that the cumulative incidence of NAION over 36 months was 8.9% in patients with diabetes taking semaglutide, compared with 1.8% in those using other diabetes medications. In patients who were overweight or obese, the incidence was 6.7% versus 0.8%. However, these figures represent the 3-year cumulative incidence of events in a specialized clinical group, not the overall annual incidence in the general population, which is approximately 2 to 10 cases per 100,000 each year. Nevertheless, the observational design of the study and the specific nature of the patient group present potential limitations. The findings show an association but do not prove causation. Therefore, although semaglutide may be associated with a higher risk of NAION, the absolute risk is low, and larger studies are needed.
Semaglutide and Other Eye Diseases and Biological Conditions
Changes in blood sugar levels in the body can affect the shape of the eye’s natural lens, which can lead to blurred vision in some patients who start taking semaglutide. As people age, the natural lens becomes less flexible and elastic, so it may take longer to stabilize when the body undergoes changes in blood sugar levels. As a result, older patients are more likely to experience this temporary side effect. It usually resolves after 3-4 months.
People with type 2 diabetes sometimes have unusually high blood sugar levels, which can cause bleeding in the eye. This can lead to diabetic eye disease and/or diabetic retinopathy. Some clinical studies have found that a small number of people taking Ozempic® (semaglutide) experience worsening of previously diagnosed diabetic retinopathy. Most people who take the medication are not affected, and medical researchers are working to better understand the long-term effects of semaglutide on diabetic retinopathy in people with type 2 diabetes.
In addition, a small number of patients taking GLP-1 agonists such as semaglutide, have developed macular edema (swelling caused by a buildup of fluid in the macula—the area in the center of the retina responsible for seeing detail in normal vision). As a result, they experience blurred vision. Diabetic retinopathy is the most common cause of macular edema (diabetic macular edema), but other conditions can also cause it. Studies are currently underway to better understand this potential side effect.
A retrospective cohort study planned for publication by the American Academy of Ophthalmology examined whether GLP-1 agonists affect the risk of age-related eye diseases, such as age-related macular degeneration (AMD), cataracts and glaucoma, in an at-risk population. It concluded that these medications may reduce the risk of developing both wet and dry AMD compared with several diabetes and lipid-lowering medications. However, it noted the need for future prospective studies to confirm its findings.
The FDA approved semaglutide for weight loss under the brand name Wegovy (2,4 mg weekly). It is increasingly being used off-label through Ozempic ® and Rybelsus®, as health insurance coverage varies across countries and insurance plans and funds. Healthcare providers and regulators in many countries have expressed concern about the off-label use of the drug for weight loss, especially among people who do not have diabetes. This off-label use has raised ethical and medical concerns, particularly regarding availability for people with diabetes and the potential side effects of unsupervised use. According to the FDA, patients are advised to obtain semaglutide only from registered pharmacies and licensed healthcare providers to minimize public health risks.
As we navigate this complex situation, we need to have informed discussions about responsible prescribing practices and patient education to successfully reduce these risks and ensure that patients understand the importance of taking medications as prescribed, rather than following trends influenced by anecdotal evidence and social media. Clinicians should also be cautious with at-risk patients who report visual symptoms.
Patients are not currently advised to stop taking semaglutide
However, if you are considering treatment with this medication, it is advisable to consult your doctor first to determine the best treatment for you based on your individual risks.
For those already taking the medication, we recommend that they do so only under the strict supervision of their treating physician and visit their ophthalmologist regularly, who should be informed that the patient is taking semaglutide.
If diagnosed with diabetic retinopathy, patients should strictly follow their ophthalmologist’s recommendations on how closely they should be monitored.
Warning symptoms that require stopping the medication immediately and notifying the ophthalmologist monitoring the patient: sudden onset of blurred vision, distorted vision, or flashes and floaters in the eyes.
Sources:
- The Rise of Ozempic for Weight Loss Sparks Ethical Concerns | Columbia University Department of Psychiatry. [cited 2025 Jan 15]
- Commissioner O of the. FDA. FDA; 2021. [cited 2025 Jan 15]. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014
- Poonja S, Chen JJ. Re-examining the putative association between GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy. Ann Eye Sci 2025;10:5–5
- Mailhac A, Pedersen L, Pottegård A, et al. Semaglutide (Ozempic®) use in denmark 2018 through 2023 ‒ user trends and off-label prescribing for weight loss. Clin Epidemiol 2024;16:307–18
Stay informed
Subscribe to our email newsletter to receive interesting and useful information.
Related Blogs
- 26/06/2025
Pentagram Eye Hospital is nominated for a golden statuette
Pentagram Eye Hospital for the second year is a finalist for a golden statuette at the Annual Medical Awards in.
Read More
- 02/03/2026
Bulgaria is one of the 3 countries – ‘white spots’ on the map of the European Union without an expert center for rare eye diseases
At the end of last week, we marked the International Day of Solidarity with People Living with Rare Diseases. Rare.
Read More